Home » Stocks » STOK

Stoke Therapeutics, Inc. (STOK)

Stock Price: $69.06 USD -0.75 (-1.07%)
Updated Jan 20, 2021 1:14 PM EST - Market open
Market Cap 2.56B
Revenue (ttm) n/a
Net Income (ttm) -47.84M
Shares Out 33.27M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $69.06
Previous Close $69.81
Change ($) -0.75
Change (%) -1.07%
Day's Open 69.65
Day's Range 68.82 - 71.58
Day's Volume 48,790
52-Week Range 16.80 - 71.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...

Seeking Alpha - 1 month ago

Stoke Therapeutics is working in cutting edge science, however it is in early stages. It already has a very high valuation.

Business Wire - 1 month ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...

Business Wire - 1 month ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...

Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: COTY, DHR, FL, BH, BHVN
Business Wire - 1 month ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...

Business Wire - 1 month ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...

Business Wire - 2 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...

Business Wire - 3 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...

Business Wire - 4 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.

Business Wire - 4 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.

Business Wire - 5 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.

Business Wire - 5 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.

Business Wire - 5 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.

Business Wire - 6 months ago

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Stoke Therapeutics, Inc. (STOK).

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Stoke Therapeutics.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Stoke Therapeutics.

The Motley Fool - 1 year ago

After top performance in August, the biotech was hit hard.

The Motley Fool - 1 year ago

Can their share prices continue to climb?

Other stocks mentioned: EIDX
Market Watch - 1 year ago

Stoke Therapeutics Inc. shares rocketed 46% in their trading debut Wednesday, after the company's initial public offering priced above its $14 to $16 price range.

Benzinga - 1 year ago

Stoke Therapeutics, Inc. opened Wednesday morning at $27.21 per share.

About STOK

Stoke Therapeutics, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 an... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2019
CEO
Edward Kaye
Employees
56
Stock Exchange
NASDAQ
Ticker Symbol
STOK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for STOK stock is "Buy." The 12-month stock price forecast is 57.63, which is a decrease of -16.55% from the latest price.

Price Target
$57.63
(-16.55% downside)
Analyst Consensus: Buy